Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00959036

Public ClinicalTrials.gov record NCT00959036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Seamless, Phase 1/2, Multiple Ascending Dose, Proof Of Concept Study Of ATN-103 Administered To Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.

Study identification

NCT ID
NCT00959036
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Ablynx, a Sanofi company
Industry
Enrollment
252 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2009
Primary completion
Dec 31, 2010
Completion
Dec 31, 2010
Last update posted
Jan 29, 2013

2009 – 2011

United States locations

U.S. sites
37
U.S. states
22
U.S. cities
35
Facility City State ZIP Site status
Investigational Site Birmingham Alabama 35209
Investigational Site Huntsville Alabama 35801
Investigational Site Peoria Arizona 85381
Investigational Site Scottsdale Arizona 85258
Investigational Site Riverside California 92501
Investigational Site Upland California 91786
Investigational Site Bridgeport Connecticut 06606
Investigational Site Newark Delaware 19713
Investigational Site Lake Mary Florida 32746
Investigational Site Ocala Florida 34474
Investigational Site Orlando Florida 32804
Investigational Site Port Orange Florida 32127
Investigational Site Vero Beach Florida 32960
Investigational Site Coeur d'Alene Idaho 83814
Investigational Site Frederick Maryland 21702
Investigational Site West Yarmouth Massachusetts 12672
Investigational Site Lansing Michigan 48910
Investigational Site Freehold New Jersey 07728
Investigational Site Albuquerque New Mexico 87108
Investigational Site Mineola New York 11501
Investigational Site Charlotte North Carolina 28210
Investigational Site Hickory North Carolina 28601
Investigational Site Winston-Salem North Carolina 27103
Investigational Site Winston-Salem North Carolina 27157
Investigational Site Columbus Ohio 43213
Investigational Site Oklahoma City Oklahoma 73103
Investigational Site Oklahoma City Oklahoma 73139
Investigational Site Tulsa Oklahoma 74104
Investigational Site Lake Oswego Oregon 97035
Investigational Site Allentown Pennsylvania 18103
Investigational Site Columbia South Carolina 29204
Investigational Site Myrtle Beach South Carolina 29572
Investigational Site Nashville Tennessee 37205
Investigational Site Dallas Texas 75235
Investigational Site Houston Texas 77004
Investigational Site San Antonio Texas 78217
Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00959036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 29, 2013 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00959036 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →